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Abstract
Background: Despite the considerable amount of evidence from randomized controlled trials and meta-
analyses, uncertainty remains regarding the efficacy and safety of high-frequency oscillatory ventilation as
compared to conventional ventilation in the early treatment of respiratory distress syndrome in preterm
infants. This results in a wide variation in the clinical use of high-frequency oscillatory ventilation for this
indication throughout the world. The reasons are an unexplained heterogeneity between trial results and
a number of unanswered, clinically important questions. Do infants with different risk profiles respond
differently to high-frequency oscillatory ventilation? How does the ventilation strategy affect outcomes?
Does the delay – either from birth or from the moment of intubation – to the start of high-frequency
oscillation modify the effect of the intervention? Instead of doing new trials, those questions can be
addressed by re-analyzing the individual patient data from the existing randomized controlled trials.
Methods/Design: A systematic review with meta-analysis based on individual patient data. This involves
the central collection, validation and re-analysis of the original individual data from each infant included in
each randomized controlled trial addressing this question.
The study objective is to estimate the effect of high-frequency oscillatory ventilation on the risk for the
combined outcome of death or bronchopulmonary dysplasia or a severe adverse neurological event. In
addition, it will explore whether the effect of high-frequency oscillatory ventilation differs by the infant's
risk profile, defined by gestational age, intrauterine growth restriction, severity of lung disease at birth and
whether or not corticosteroids were given to the mother prior to delivery. Finally, it will explore the
importance of effect modifying factors such as the ventilator device, ventilation strategy and the delay to
the start of high-frequency ventilation.
Discussion: An international collaborative group, the PreVILIG Collaboration (Prevention of Ventilator
Induced Lung Injury Group), has been formed with the investigators of the original randomized trials to
conduct this systematic review. In the field of neonatology, individual patient data meta-analysis has not
been used previously. Final results are expected to be available by the end of 2009.
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Clinical significance of respiratory distress syndrome in 
preterm infants
Prematurely born infants frequently suffer from respira-
tory distress syndrome (RDS). Of all infants born at a ges-
tational age of less than 30 weeks, 90% require
mechanical ventilation and almost 80% are treated with
exogenous surfactant. This proportion is highest among
the most immature infants [1]. Despite the advances in
neonatal respiratory care, a considerable number of those
infants develop chronic lung disease of prematurity,
called bronchopulmonary dysplasia (BPD). Of all infants
with a birth weight of less than 1500 g, 23% are oxygen
dependent at the postmenstrual age of 36 weeks [2]. The
risk for BPD is particularly high for the extremely preterm
infant born at 26 weeks gestation or less: 44% to 74%
need supplemental oxygen at 36 weeks postmenstrual age
[3-6]. Bronchopulmonary dysplasia is associated with
prolonged neonatal intensive care, home oxygen use,
recurrent respiratory infections often requiring hospitali-
zation, feeding difficulties with impaired growth and neu-
rodevelopmental delay [7-9].
Although the pathogenesis of BPD is multifactorial,
mechanical ventilation is one of the most important caus-
ative factors. Alveolar overexpansion secondary to high
lung volume ("volutrauma") as well as alveolar injury due
to repetitive alveolar recruitment-derecruitment ("atelec-
trauma") are pathogenetic mechanisms of "ventilation-
induced lung injury" (VILI) that may lead to BPD [10].
Both phenomena occur during conventional mechanical
ventilation (CV) of atelectasis-prone lungs, such as in pre-
mature infants with RDS.
In the late seventies "high-frequency oscillatory ventila-
tion" (HFOV) was developed as a new ventilation tech-
nique, using tidal volumes smaller than anatomical dead
space delivered at a very high rate of 600 to 900 per
minute, thus avoiding the large volume swings seen with
CV. High-frequency oscillatory ventilation can be deliv-
ered using a piston pump or an oscillating electromag-
netic membrane (so called "true oscillators") that
generate true negative pressure during exhalation phase or
using a high-frequency flow interrupter where a Venturi-
system at the exhalation valve is responsible for creating a
negative pressure (high-frequency flow interruption or
HFFI). HFOV proved to be an effective way to ventilate
both normal and abnormal lungs [11,12] and in animal
models of RDS, it caused less lung injury compared to CV
[13]. Therefore, HFOV was expected to result in less mor-
tality and less BPD, when used as the primary mode of
ventilation in the treatment of RDS in preterm infants.
Randomized trials of elective HFOV versus CV in preterm 
infants with RDS
The first randomized controlled trial, the multi-centre
HIFI trial published in 1989, showed no benefit of HFOV
for pulmonary outcomes and an increased risk of adverse
neurological outcome (intracranial haemorrhage and
periventricular leukomalacia) [14]. However, the trial was
criticized afterwards because the HFOV strategy did not
use lung volume recruitment ("optimal lung volume strat-
egy" or OLVS) and because many centers lacked experi-
ence with this new ventilation technique. Numerous
randomized trials followed over the next 15 years, most of
them applying the "optimal lung volume strategy" with
HFOV. However, the positive effects of HFOV found in
animal experiments was not reproduced consistently in
the clinical trials with preterm infants. Results differed
substantially between trials, both for the benefits (reduc-
tion of BPD) as well as for the harms (increased risk of
intracranial haemorrhage). Although the first Cochrane
review, which was published in 1996, showed a modest
benefit from HFOV over CV in terms of pulmonary out-
come, HFOV did not become the standard of care in the
ventilatory management of preterm infants with RDS.
Summary of systematic reviews of aggregate data in 2008
Several meta-analyses about the effects of the early use of
HFOV in preterm infants exist [15-22]. The updated
Cochrane review [22] identified 15 trials including a total
number of 3585 premature infants. Results of the meta-
analyses showed no difference in mortality [relative risk
(RR) for death at 36–37 weeks postmenstrual age or dis-
charge: 0.98, 95% confidence interval (95% CI) 0.83–
1.14] and a small but significant reduction in the risk of
BPD at 36–37 weeks postmenstrual age or discharge in
survivors (RR 0.89, 95% CI 0.81 – 0.99). However, there
was significant heterogeneity between trials (p = 0.002, I2
= 63.2%). A priori planned subgroup analyses based on
the HFOV strategy – i.e. whether or not an OLVS was used
– could not explain this heterogeneity, which persisted in
the subgroup of trials with OLVS (p = 0.002). The review
also demonstrated a non-significant trend towards an
increased risk of adverse neurological events: RR for severe
grade intracranial haemorrhage 1.11 (95% CI 0.95 –
1.30), and for periventricular leukomalacia 1.10 (95% CI
0.85 – 1.43). This result was moderately heterogeneous
(not statistically significant, p = 0.11). In the subgroup
analysis of trials not using a OLVS the risk for adverse neu-
rological events was significantly higher [RR for severe
grade intracranial haemorrhage 1.45 (95% CI 1.09–1.93),
and for periventricular leukomalacia 1.64 (95% CI 1.02–
2.64)], and the result was homogeneous, suggesting that a
HFOV strategy aiming at low pressures and, thus, low lung
volumes, may be associated with adverse neurological
outcome.Page 2 of 13
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tilation with CV, used cumulative meta-analysis and
meta-regression analysis to explore heterogeneity [19-21].
In the meta-analysis by Thome (17 trials, 3776 patients),
the difference in risk of death or BPD did not reach statis-
tical significance (OR 0.87, 95% CI 0.75 – 1.00). How-
ever, HFOV was associated with a significantly increased
risk for air leak (OR 1.23, 95% CI 1.06 – 1.44). Cumula-
tive meta-analysis suggested that the benefit from HFOV
over CV decreased after the introduction in clinical trials
of surfactant replacement therapy and of a more "lung
protective" conventional ventilation strategy [19,20].
Despite all these additional subgroup analyses, cumula-
tive meta-analyses and meta-regression analyses, hetero-
geneity between trial results remains largely unexplained.
Because several important questions remain unanswered,
the available evidence is unable to guide clinicians in
making decisions about patient care: Is HFOV equally
effective in all preterm infants with RDS or is it possible to
identify certain subgroups of infants with specific risk pro-
files which benefit more or less from HFOV than others?
To what extent does the ventilation strategy, both for
HFOV and for CV, affect the difference in outcome
between both ventilation modes? What is the influence of
the delay between birth and the start of HFOV on the lung
protective effects of HFOV in preterm infants? Hence, the
controversy whether or not we should use HFOV as the
primary mode of ventilation in preterm infants with RDS
remains [23].
The aim of this project is to extend the reviews based on
aggregate data by collecting and reanalyzing the original
data on each individual infant in each trial ("individual
patient data" or IPD meta-analysis) to help answer these
remaining questions. The use of IPD will allow for more
appropriate and flexible analyses of both subgroups and
outcomes. This unique reanalysis will provide more
detailed information, thereby improving the applicability
of the evidence in clinical practice.
Limitations of the reviews using published, aggregate data
• Published aggregate data is variable in outcome defini-
tion, e.g. for important outcomes such as "bronchopul-
monary dysplasia", or in outcome reporting, thereby
making pooling of trial results difficult or sometimes
impossible.
• The information from the published aggregate data
required for the subgroup analyses based on ventilator
device or ventilation strategy is often imprecise (e.g. using
wide ranges of settings) or absent. In addition, some trials
cannot be included in those subgroup analyses, because
they used more than one type of high-frequency ventilator
(e.g. high-frequency oscillator and high-frequency flow
interrupter) [24,25], but only report on outcomes for the
whole study population.
• It is unclear whether some preterm infants benefit more
or less from HFOV than others, based on their clinical
characteristics such as the gestational age at birth, the
severity of lung disease, or the intra-uterine growth. Only
a few trials report outcomes separately for different groups
of preterm infants, thereby defining the groups either by
gestational age, but using different cut-off points [24,26],
or by birth weight [27].
• It remains uncertain whether the delay between birth
and the start of HFOV, or the time a premature infant was
exposed to conventional ventilation prior to HFOV (i.e.
the delay between the start of mechanical ventilation and
the start of HFOV) are important factors in determining
outcome with HFOV. For several trials, this information is
not provided in the published aggregate data. Other trials
have a very wide range of timing within their study popu-
lation, making the information less useful for subgroup
analyses. So, it is difficult to make recommendations with
regard to the optimal timing of HFOV.
Ways of overcoming these limitations by using individual 
patient data
• Obtaining individual patient data from each trial will
improve the quality of the data. It will allow direct assess-
ment of patient eligibility for inclusion in the trial and
analysis of all randomized infants on an intention-to-treat
basis. Importantly, it will allow redefining patient charac-
teristics and outcomes uniformly across trials, resulting in
more accurate pooled estimates of effects. For example,
bronchopulmonary dysplasia can be defined at the same
time point (e.g. 36 weeks' postmenstrual age) using the
same criteria (e.g. oxygen dependency) for all trials.
• For certain trials, it might be possible to obtain informa-
tion on measured, but previously unreported outcomes.
For example, older trials report only on the "original" def-
inition of BPD, i.e. oxygen dependency at 28 days postna-
tal age. However, if in those trials the last day of oxygen
requirement was recorded for each infant, BPD at 36
weeks postmenstrual age can be calculated. Furthermore,
trialists may be able to provide missing outcome data.
• Through more detailed information from the trial pro-
tocol on the one hand and the use of information at the
individual patient level on the other hand, the ventilation
strategy which was used in a trial, both for HFOV and for
CV, can be assessed more accurately. Furthermore, more
detailed information can be obtained regarding the tim-
ing of HFOV (i.e. delay between birth and randomization,
delay between intubation and randomization). This will
improve the quality of the subgroup analyses based onPage 3 of 13
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those variable as co-variates in multi-variate regression
analyses.
• Importantly, subgroup analyses can be done for a
number of patient risk factors using the individual study
infant's risk data rather than the average risk of the whole
study population. This will allow investigating the effect
of HFOV in certain subgroups of preterm infants (e.g.
extremely preterm infants versus less preterm infants,
small-for-gestational-age infants versus appropriate-for-
gestational-age infants).
• Individual patient data will allow doing time-to-event
pooled analyses for outcomes such as death, duration of
mechanical ventilation and oxygen dependency.
Methods and design
Objectives
The main questions to be addressed by this study are:
• Does high-frequency ventilation, compared to conven-
tional ventilation, offer a clinically important benefit in
terms of more survival without BPD, without increasing
the risk for adverse neurological events such as severe
intracranial haemorrhage or periventricular leukomalacia,
when used as the primary mode of ventilation in preterm
infants with respiratory distress syndrome?
• Do the effects of HFOV differ according to the risk pro-
file of the patient in terms of lung immaturity (gestational
age at birth, antenatal corticosteroids or not), fetal growth
(birth weight for gestational age), severity of lung disease
(index of respiratory failure, chorioamnionitis), the tim-
ing of HFOV (delay between birth/intubation and rand-
omization).
• How do the following intervention-related factors and
co-interventions modify the treatment effect: high-fre-
quency ventilator device and/or settings, ventilation strat-
egy ("optimal lung volume recruitment" or not for HFOV,
"lung protective strategy" or not for CV), exogenous sur-
factant therapy (timing of first dose, number of doses),
postnatal treatment with corticosteroids.
Methods
The method will be a systematic review of randomized
controlled trials based on individual patient data. This
means that for each infant randomized in each of the
available trials, a predefined number of data items regard-
ing baseline characteristics, experimental and control
intervention, co-interventions and neonatal outcomes
will be collected, stored in a central database, re-analyzed
and pooled in a meta-analysis.
Identifying studies
The trials included in the updated Cochrane review of
aggregate data about HFOV [22] will be included in the
IPD analysis. The search will be repeated using the same
search strategy and databases (Medline, Embase,
Cochrane Controlled Trial Register) to find more recent
randomized controlled trials. Furthermore, experts in the
field and trialists will be asked to report on other unfound
or unpublished trials.
Inclusion and exclusion criteria for studies
The inclusion and exclusion criteria for the types of study
design, participants and interventions are listed below.
Eligibility of trials will be assessed independently and
unblinded for author and journal by two members of the
Secretariat. Any differences in opinion regarding eligibil-
ity will be resolved by discussion. If individual patient
data are unavailable from an available trial, the trial will
still be included in the review and aggregate data will be
used for sensitivity analyses.
a. Study design
Studies will be included if they were randomized control-
led trials. Studies using quasi-randomization will be
excluded.
b. Participants
Studies will be included if participants were preterm (< 35
weeks gestational age) or low birth weight (< 2000 g birth
weight) infants with pulmonary dysfunction due to respi-
ratory distress syndrome who were considered to require
assisted ventilation.
c. Intervention
Studies will be included if the intervention was elective
high-frequency oscillatory ventilation compared with
conventional ventilation. HFOV could be delivered either
with a true oscillator using a piston pump or an oscillating
electromagnetic membrane, or with a high-frequency
flow interrupter using a Venturi-system. The intervention
is classified as "elective" if infants were randomized early
in the course of their disease soon after mechanical venti-
lation was commenced, meaning that HFOV was used as
the primary mode of ventilation. In contrast, trials are
classified as "rescue" when patients were randomized only
after meeting certain failure criteria on conventional ven-
tilation. Those "rescue" trials will be excluded from the
review. The control intervention may be any type of con-
ventional, i.e. "tidal", time-cycled ventilation: pressure- or
volume controlled, synchronized or not, with or without
pressure-support, with or without volume-guarantee.
Data management
A new set of pre-specified and clearly defined variables
(both for patient-level and trial-level factors as well as forPage 4 of 13
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used. An Excell spreadsheet is designed for the data collec-
tion. Trialists are allowed to provide the individual patient
data in any format. Data transformation to the new for-
mat and coding system will be done by the trialist himself
or by the PreVILIG investigators' team. The individual
patient data will be de-identified by the original investiga-
tors before they are sent to the PreVILIG Data Manage-
ment Team. It will not include any patient identifying
information such as names or addresses. Only authorized
personnel (members of the PreVILIG Secretariat or Data
Management Team) will have access to the data. However,
Collaborators will continue to have control over how data
from their trial is used. The individual patient data will be
recoded as required and stored in a custom designed data-
base. The data will not be used for any other purpose with-
out permission of the collaborators.
The data will be checked with respect to range, internal
consistency, consistency with published reports and miss-
ing items. Trial details such as randomization methods
and intervention details will be crosschecked against pub-
lished reports, trial protocols and data collection sheets.
Inconsistencies or missing data will be discussed with the
individual trialists and attempts will be made to resolve
any problems by consensus. Each trial will be analyzed
individually, and the resulting analyses and trial data will
be sent to the trialists for verification.
Data items requested from trialists
During a Collaborative Group Meeting, a list of data items
to collect for each infant was proposed by the Secretariat
to the PreVILIG collaborators. After discussion, a final list
of data items and a recoding system for each of the varia-
bles was compiled. More detailed definitions of data
items listed below can be found in Table 1. Details of the
suggested coding system can be found in the Additional
File PreVILIG Coding System.
a. Trial-level information
• Informed consent
• Dates trial opened and closed to accrual
• Total number of patients randomized
Table 1: Definitions for patient characteristics at enrolment, data on trial interventions and co-interventions, and neonatal outcomes.
Variable Definition
Patient-level information on characteristics at enrolment
Complete course of antenatal corticosteroids A course of at least 2 doses started > 48 hours before delivery or completed > 24 hours 
before delivery
Antenatal corticosteroids, any treatment Any antenatal treatment with corticosteroids, regardless of the interval with delivery
Chorioamnionitis As defined in the trial
Oxygenation index (OI) OI = MAP × FiO2 × 100/PaO2 With
MAP = mean airway pressure
FiO2 = fractional inspired oxygen
PaO2 = partial arterial oxygen tension
Patient-level information on trial intervention and co-interventions
MAP at stabilization Mean airway pressure in the first 24 hours after randomization.
FiO2 at stabilization Fractional inspired oxygen in the first 24 hours after randomization.
Postnatal corticosteroids Postnatal treatment with corticosteroids for the prevention or treatment of 
bronchopulmonary dysplasia
Early administration of cyclo-oxygenase inhibitor Administration of indomethacin or ibuprofen in the first 24 hours of life in order to prevent 
patent ductus arteriosus or intracranial haemorrhage
Neonatal outcomes
Death Death before discharge from neonatal intensive care unit (NICU)
BPD at 36 weeks PMA Oxygen therapy at the postmenstrual age of 36 weeks
Severe adverse neurological event Intracranial haemorrhage grade 3 or 4, and/or cystic periventricular leukomalacia
Gross pulmonary air leak Pneumothorax and/or pneumomediastinum and/or pneumopericardium
PDA requiring treatment Patent ductus arteriosus requiring treatment with non-steroidal anti-inflammatory drugs or 
surgery
Any pulmonary air leak Gross pulmonary air leak and/or pulmonary interstitial emphysema (PIE)
Neurological disability Motor and/or cognitive and/or auditory and/or visual impairmentPage 5 of 13
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• Stratification factors used
• Methods of allocation concealment
• Blinding of outcome assessment
• Ventilator management in experimental arm
(HFOV): ventilator device, frequency and inspiratory-
to-expiratory-time ratio (tI:tE), initial settings of mean
airway pressure (MAP), strategy of lung volume
recruitment and stabilization on HFOV, target value
for fractional inspired oxygen concentration (FiO2) at
stabilization
• Ventilator management in control arm (CV): venti-
lator device, synchronization, initial settings of peak
inspiratory pressure (PIP), end expiratory pressure
(PEEP), rate and inspiratory time, target tidal volume
• Target values for arterial carbon dioxide tension
(PaCO2) during mechanical ventilation
• Cross over to alternative ventilation mode after
meeting predefined failure criteria, definition of fail-
ure criteria
• Weaning protocol for HFOV: HFOV until extuba-
tion/switch to CV when meeting certain criteria/switch
to CV after a preset number of days on HFOV
• Protocol for surfactant replacement therapy: criteria
for first dose, timing of first dose, type of surfactant
• Criteria for postnatal treatment with corticosteroids
for the prevention or treatment of BPD
b. Patient-level information: characteristics at study entry
• Unique identifier coded for anonymity
• Gestational age at birth
• Birth weight
• Sex
• Apgar score after 5 minutes
• Postnatal age at intubation
• Postnatal age at randomization
• Prenatal corticosteroids therapy (complete course or
any steroids administered)
• Presence of chorioamnionitis (as defined in the trial)
• Severity of lung disease at study entry: partial arterial
oxygen tension (PaO2), FiO2, MAP before/at randomi-
zation
• Multiple birth and rank order of birth
c. Patient-level information: data on experimental and control 
intervention and co-interventions
For all infants:
• FiO2 and MAP at stabilization on mechanical venti-
lation¶
• Partial arterial carbon dioxide tension (PaCO2) dur-
ing the first 72 hours#
• Surfactant replacement therapy
• Type of surfactant
• Postnatal age at first dose of surfactant
• Number of surfactant doses
• Early administration of cyclo-oxygenase inhibitor
(indomethacin or ibuprofen)
• Postnatal treatment with corticosteroids for the pre-
vention or treatment of BPD
• Postnatal age at start of postnatal corticosteroid
treatment
For infants in the experimental arm (HFOV)
• Specific make of HFOV ventilator
• Setting of high-frequency rate in the first 24 hours¶
For infants in the control arm (CV)
• Specific make of ventilator
• Synchronization of ventilation to spontaneous respi-
ration or not
• Ventilator rate during the first 72 hours#
• PEEP during the first 72 hours#
• PIP during the first 72 hours#
d. Patient-level information: data on neonatal outcome
• Death before discharge and age at deathPage 6 of 13
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• Total number of days on mechanical ventilation
• Postnatal age at last day of nasal continuous positive
airway pressure (CPAP)
• Postnatal age at last day of oxygen therapy
• Gross pulmonary air leak (pneumothorax, pneumo-
mediastinum, pneumpericardium)
• Pulmonary interstitial emphysema
• Worst grade of intracranial haemorrhage¶¶
• Cystic periventricular leukomalacia
• Worst stage of retinopathy of prematurity (ROP)##
• Patent ductus arteriosus requiring treatment (non-
steroidal anti-inflammatory drugs or surgical ligation)
• Patent ductus arteriosus requiring surgical ligation
• Postnatal age at discharge from neonatal intensive
care unit
• Cerebral palsy at 1–2 years corrected age + corrected
age at assessment
• Neurological disability at 1–2 years corrected age +
corrected age at assessment
• Cerebral palsy at 5–8 years corrected age + corrected
age at assessment
• Neurological disability at 5–8 years corrected age +
corrected age at assessment
¶ All recorded values in the first 24 hours will be collected,
with a maximum of 4 values.
# All recorded values in the first 72 hours will be collected,
with a maximum of 7 values.
¶¶ Grading of intracranial haemorrhage (grade 1 – 4)
according to Papile [28]
## Staging of ROP according to International Classification
Committee [29]
Planned analyses
The section below contains a summary of the planned
analyses. A detailed analysis plan will be discussed and
agreed upon by all the PreVILIG Collaborators prior to
any data analysis.
Analysis will aim to be of all infants ever randomized and
will be based on intention to treat. In the main analysis a
two-stage approach will be taken: outcomes will be ana-
lyzed in their original trial and then these separate results
will be combined in a meta-analysis to give an overall
measure of effect. Both a fixed effect and a random effects
model will be used. The assumption of homogeneity will
be tested using the chi squared test. The I2 statistic will also
be used to assess consistency of results.
If, for a certain outcome, a trial has less than 80% of the
complete trial data presented in individual patient data,
the trial will not be included in the meta-analysis for that
specific outcome.
1. Outcomes to be analyzed
The main analyses comparing the effect of high-frequency
ventilation with conventional ventilation will be under-
taken for all outcomes listed below. The planned sub-
group and sensitivity analyses will be restricted to the
main outcomes only, or to the main outcomes plus a few
key additional outcomes. Definitions of outcomes are
listed in Table 1.
a. Main outcomes
• Death or BPD at 36 weeks' postmenstrual age
• Death or severe adverse neurological event
• Death or BPD at 36 weeks' postmenstrual age or
severe adverse neurological event
b. Secondary outcomes
• death before discharge
• postnatal age at final extubation
• total number of days of mechanical ventilation
• postnatal age at last day of nasal CPAP
• postnatal age at last day of oxygen therapy
• Gross pulmonary air leak
• Any pulmonary air leak
• Severe intracranial haemorrhage (grade 3 or 4)
• Cystic periventricular leukomalacia
• Retinopathy of prematurity (stage 2 or more)Page 7 of 13
(page number not for citation purposes)
BMC Pediatrics 2009, 9:33 http://www.biomedcentral.com/1471-2431/9/33• Cross-over from assigned mode to alternative mode
of ventilation after meeting trial-specific failure criteria
• Patent ductus arteriosus requiring treatment
• Patent ductus arteriosus requiring surgical ligation
• Postnatal age at discharge from NICU
• cerebral palsy at 1–2 years corrected age
• Neurological disability at 1–2 years corrected age
• Cerebral palsy at 5–8 years corrected age
• Neurological disability at 5–8 years corrected age
2. Planned subgroup analyses
a. Trial-level characteristics
The effect of HFOV compared with CV may vary across tri-
als because different types of ventilators or different venti-
lation strategies were used. To explore this further,
analyses are planned whereby trials are grouped according
to the characteristics of the ventilator or according to the
ventilation strategy which was used.
(i) type of HFOV device
1. Trials will be grouped according to the characteristics of
the exhalation phase into "true oscillators" using either a
piston pump or an electromagnetic membrane (Hum-
mingbird, SM 3100(A), Stephan, Dufour, SLE) and "flow
interrupters" using a Venturi system (Dräger Babylog,
Infant Star).
2. Trials will be grouped according to the specific make of
HFOV ventilator.
(ii) HFOV strategy
Trials will be grouped into those that used an "optimal lung
volume strategy" (OLVS) with HFOV and those that did
not. An "optimal lung volume strategy" means that during
the initial phase of stabilization on HFOV, a higher mean
distending pressure than used during CV is used in order
to recruit collapsed lung alveoli. Effective alveolar recruit-
ment is reflected by a decrease in oxygen requirement
because of a decrease in intrapulmonary right-to-left
shunting. Ideally, oxygen requirement is expected to
become 21% (room air) once all alveoli are optimally
recruited and ventilated.
A trial will be considered as being an OLVS-trial if both of
the following elements are present in the trial protocol:
1. an initial MAP with HFOV which is 1 to 2 cmH2O
higher than with CV,
2. the preferential weaning of FiO2 before weaning of
MAP,
(iii) CV strategy
Trials will be grouped into those that used a "lung protec-
tive ventilatory strategy" (LPVS) and those that did not.
Conventional ventilation strategy will be considered as
being "lung protective" if 1) atelectrauma was avoided by
using adequate PEEP (4 cmH2O or higher), 2) volutrauma
was avoided by targeting high-normal PaCO2-values (> 40
mmHg), limiting tidal volume (7 mL/kg or less) or, if tidal
volume was not measured, using high ventilator rates (60/
min or higher), and 3) spontaneous expiration by the
infant during the inspiratory phase of the ventilator has
been avoided by using a short inspiratory time (< 0.50
sec).
Trials will be considered as "LPVS"-trials if 3 out of the 5
following criteria are mentioned in the trial protocol:
1. PEEP of 4 cmH2O or higher
2. inspiratory time of less than 0.5 sec
3. initial ventilator rate of 60/minute or higher
4. PaCO2 target range with lower limit of 40 mmHg or
higher
5. tidal volume target range with upper limit of 7 ml/
kg or less
b. Patient-level characteristics
The effect of HFOV compared with CV may be different
depending on the risk profile of the infant. The subgroup
analyses described below will address the question
whether there any particular types of preterm infants who
benefit more or less from HFOV. The analyses will take
into account each individual infant's own characteristics,
rather than relying on summary measures of the "average"
risk profile of the whole study population for a specific
trial. The subgroup analyses will be restricted to the main
outcomes plus 3 additional outcomes ("gross pulmonary
airleak", "severe intracranial haemorrhage", and "postna-
tal age of last day of oxygen therapy").
The following criteria will be used to define the risk profile
of the preterm infant:
(i) Gestational age at birth
Extremely preterm infants are at high risk of developing
BPD and could therefore theoretically benefit more from
HFOV on pulmonary outcomes than infants at lower risk.
On the other hand, they are also at higher risk of having
an intracranial haemorrhage or cerebral white matterPage 8 of 13
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HFOV is associated with an increased risk of adverse neu-
rological outcome.
To determine whether HFOV offers a clinically relevant
benefit in certain gestational age groups, subgroup analy-
ses will be performed according to gestational age at birth
as follows:
▪ < 26 weeks (up to 25 weeks and 6 days)
▪ 26 – 28 weeks (from 26 weeks up to 28 weeks and 6
days)
▪ 29 – 31 weeks (from 29 weeks up to 31 weeks and 6
days)
▪ 32 weeks and more
(ii) Severity of lung disease at onset
The severity of respiratory failure not only depends on the
degree of immaturity of the infant at birth, but is also
affected by factors such as the antenatal administration of
corticosteroids, or the presence of chorioamnionitis and/
or perinatal asphyxia.
To determine whether HFOV has more effect in infants
with more severe lung disease at birth, infants will be
grouped according to their oxygenation index at trial
entry. The oxygenation index will be calculated for each
individual infant as follows: OI = FiO2 × MAP × 100/PaO2.
Three subgroups of severity of lung disease will be defined
[30].
• Mild respiratory disease: OI < 4
• Moderate respiratory disease: OI 4 – 9
• Severe respiratory disease: OI > 9
(iii) Birth weight for gestational age
Intrauterine growth restriction is an important prenatal
risk factor for BPD in very preterm infants [31]. Being at
higher risk, growth restricted infants may benefit more
from HFOV than other infants. Therefore, a subgroup
analysis will be done for infants who are small-for-gesta-
tional age (SGA) and infants who are not SGA. Infants will
be categorized within each trial, first using the trial's own
definition, and secondly, using a new PreVILIG definition
(i.e.: a birth weight below the 10th percentile for gesta-
tional age according to their sex, using recent reference
data for birth weight for premature infants)[32].
(iv) Antenatal administration of corticosteroids
An intervention that has changed the outcome of preterm
infants dramatically is the antenatal administration of
corticosteroids. It has proven to decrease the risk of death,
severe IRDS and intracranial haemorrhage [33]. Therefore
infants will be grouped according to whether or not they
received corticosteroids antenatally. Depending on the
availability of information from the trials, subgroup anal-
yses will be done for:
1) infants who received any corticosteroids antenatally,
2) infants who received a complete course of antenatal
corticosteroids
3) infants who received a complete course of antenatal
corticosteroids with the last dose within 7 days before
birth.
(iv) Timing of commencement of HFOV
Animal experiments suggest that HFOV is most successful
in protecting the lungs if applied very early in the course
of the disease and with minimal prior conventional venti-
lation. In order to differentiate between the importance of
the postnatal age per se and the importance of the period
of CV prior to the start of HFOV, two subgroup analyses
are planned: a first subgroup analysis based on the delay
between birth and randomization ("postnatal age" as
effect modifying factor) and a second one based on the
delay between intubation and randomization ("period of
CV prior to HFOV" as effect modifying factor). Subgroups
will be defined as follows:
• Delay < 1 hour
• Delay 1 – 4 hours
• Delay > 4 hours
All subgroup analyses based on patient characteristics will
be performed in 2 stages. First, subgroups are analyzed
within their own trial. Then, results of those analyses are
pooled across trials to calculate a summary effect for each
risk stratum. The subgroup analyses will be done for the
main outcomes only.
3) Planned sensitivity analyses
a) To assess whether the results are robust to trial design
and quality, the following sensitivity analyses will be per-
formed:
• Exclusion of trials with small sample size (< 100
study patients)Page 9 of 13
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or more of randomized patients in at least one treat-
ment arm)
• Exclusion of trials without blinding of outcome
assessment for outcomes such as severe intracranial
haemorrhage, cystic periventricular leukomalacia and
cerebral palsy
b) To assess whether the results are robust to different
methods of analysis, the following sensitivity analyses
will be performed:
• Comparison of analyses using fixed effect model and
random effects model
• Comparison of analyses using IPD only and analyses
using IPD and aggregate data if IPD are unavailable
c) To assess whether the results are robust to the inclusion
or exclusion of trials with missing IPD, a sensitivity anal-
ysis will be done where IPD will be combined with aggre-
gate data from trials with missing IPD.
4) Additional analyses
Secondary, one-stage analyses will be conducted which
will explore the relation between a number of trial-level
and patient-level factors as co-variates and the effect of
HFOV as the outcome. The influence of ventilation strat-
egy, both for HFOV and for CV, will be further explored
using this one-stage approach. A multi-variate modelling
approach will be used including "trial" as a co-variate and
taking into account possible interactions between differ-
ent variables. Hence, predictive models for successful out-
come can be developed and tested in a large study
population.
Ethical considerations
Informed consent has been given by the participants pre-
viously, at enrolment in the original trial. In this project,
the patient data will not be used for any other purpose
than the one in the original trial. This study is retrospec-
tive, meaning that no new patient data will be generated.
Therefore, informed consent specifically for this project
was not considered necessary. The individual patient data
are made available through an agreement between all tri-
alists of the Collaborative Group and the members of the
Secretariat. The trialists remain the custodian of their orig-
inal individual trial data at all times.
Project management
For the purpose of this project, an international Collabo-
rative Group, the PreVILIG Collaboration, is being
formed. The Collaboration consists of 3 groups with spe-
cific responsibilities and tasks:
a. The Secretariat
The Secretariat is the steering group which is responsible
for the project's management decisions and the daily
management of the Collaboration. Its tasks are to design
the project's protocol and analysis plan, organize the Col-
laborative Group Meetings and act as a liaison between all
the members of the Collaborative Group. Membership: F
Cools1 (project coordinator), M Offringa2 (chair), L Askie3
(responsible for Data Management Team), D Henderson-
Smart4. The Secretariat will meet once every 2 to 4
months, usually by teleconference.
1 Department of Neonatology, Universitair Ziekenhuis
Brussel, Brussels, Belgium;
2 Department of Pediatric Clinical Epidemiology, Emma
Children's University Hospital, Amsterdam, The Nether-
lands
3 NHMRC Clinical Trials Centre, University of Sydney,
Sydney, Australia
4 Centre for Perinatal Health Services Research, University
of Sydney, Sydney, Australia;
b. Trialist Group
Members of the Trialist Group will be representatives of
the eligible trials. For each trial, the first author will be
invited to become a member of the Collaboration. If con-
sidered necessary or if there was no response from the first
author, other investigators from the trials may be con-
tacted (data manager, statistician). In order to keep the
Trialists Group updated, authors of new trials or previ-
ously unknown trials may be contacted and invited to join
the Collaboration in the course of the project.
c. Advisory Group
Members of the Advisory Group are experts in various
fields of the project, such as neonatal pulmonary mechan-
ics and neonatal high-frequency ventilator performance (J
Pillow1), IPD meta-analysis methodology and statistics (L
Stewart2, C Bollen3), neonatal research and clinical epide-
miology (R Soll4). In addition, the project is closely linked
to the Cochrane Collaboration (R Soll, Coordinating Edi-
tor of the Neonatal Collaborative Review Group). Mem-
bers of the Advisory Group will be consulted from time to
time on a "on demand" basis and usually by e-mail or tel-
econference.
1 School of Women's and Infants' Health, University of
Western Australia, Perth, Australia.
2 Centre for Reviews and Dissemination, University of
York, UKPage 10 of 13
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lands
4 Department of Pediatrics, University of Vermont College
of Medicine, USA
d. Data Management Centre
The data management centre will be located at the
NHMRC Clinical Trials Centre in Sydney, Australia, and
will be coordinated by L Askie, member of the Secretariat.
It will be responsible for the storage and analyses of the
project data.
d. Collaborative Group Meetings
Collaborative group meetings will be organized on a reg-
ular basis. The members of all 3 groups will be invited to
attend those meetings. The meetings will be scheduled, if
possible, during international neonatal or paediatric con-
ferences, such as the Annual Meeting of the Pediatric Aca-
demic Societies in the USA. During those meetings,
various aspects of the project will be discussed with all the
collaborators, such the project's design and conduct, the
analysis plan, and the interpretation and reporting of the
results. The final Collaborators' meeting is scheduled for
May 2009 in Baltimore.
Funding
Unrestricted research grants have been kindly provided by
the companies Dräger and Nestlé to support the collection
of the individual patient data by the original investigators
and to organize the Collaborators' meetings. The compa-
nies are not involved in any other aspect of the project,
such as the design of the project's protocol and analysis
plan, the collection and the analyses of the project's data,
or the interpretation and the publication of the study
results.
Publication policy
The study results will be presented in a Collaborators'
meeting for discussion with all the collaborators. The
main manuscript will be prepared by the project coordi-
nator and circulated to the other members of the Secretar-
iat for revision. The revised manuscript will be circulated
to the members of the Trialist Group and Advisory Group
for comment before publication. Publications will be
authored in the name of the PreVILIG Collaboration as
follows: F Cools, L Askie, and M Offringa for the Preven-
tion of Ventilator Induced Lung Injury Collaborative
Group (PreVILIG).
Discussion
Despite the considerable amount of evidence about the
efficacy and safety of HFOV as compared with CV as the
primary mode of mechanical ventilation in preterm
infants with respiratory distress syndrome, there is a wide
variation in the use of HFOV in clinical practice because
important questions have remained unanswered. Should
we start HFOV in every preterm infant with RDS, or are
there certain types of preterm infants who benefit more or
less from HFOV than others? How do ventilation strate-
gies, both of HFOV and CV, affect outcome? Is it impor-
tant to start HFOV as soon as possible after birth or to
limit as much as possible the time the infant is exposed to
CV?
The currently available meta-analyses of randomized con-
trolled trials are unable to answer those questions because
their methodology is based on aggregate data, which has
certain limitations. To overcome those limitations, a
meta-analysis based on individual patient data instead of
aggregate data will be conducted. This approach will
improve substantially the quality of the data and will
allow for more flexible analysis of both subgroups and
outcomes.
In 2006, an international Collaboration (PreVILIG) was
started to undertake this systematic review. Submission of
the data by the participating Collaborators has been com-
pleted in November 2008 and results will be ready by
August 2009. The main publication is expected in late
2009.
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